EA200870594A1 - Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение - Google Patents

Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение

Info

Publication number
EA200870594A1
EA200870594A1 EA200870594A EA200870594A EA200870594A1 EA 200870594 A1 EA200870594 A1 EA 200870594A1 EA 200870594 A EA200870594 A EA 200870594A EA 200870594 A EA200870594 A EA 200870594A EA 200870594 A1 EA200870594 A1 EA 200870594A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activity against
binding molecules
enteroccokkki
human binding
application
Prior art date
Application number
EA200870594A
Other languages
English (en)
Other versions
EA016717B1 (ru
Inventor
Марк Тросби
Роберт Арьен Крамер
Корнелис Адриан Де Крэйф
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA200870594A1 publication Critical patent/EA200870594A1/ru
Publication of EA016717B1 publication Critical patent/EA016717B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение связано с человеческими связывающими молекулами, специфически связывающимися с энтерококками и обладающими киллерной активностью в отношении энтерококков, молекулами нуклеиновых кислот, кодирующими указанные связывающие молекулы человека, композициями, содержащими связывающие молекулы человека, и способами идентификации или получения человеческих связывающих молекул. Также человеческие связывающие молекулы могут быть использованы в диагностике, профилактике и/или лечении состояния, вызываемого Enterococcus.
EA200870594A 2006-06-06 2007-06-05 Моноклональное антитело человека, обладающее опсонизирующей фагоцитарной киллерной активностью в отношении enterococcus и staphylococcus aureus, и его применение EA016717B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81154206P 2006-06-06 2006-06-06
EP06115013 2006-06-06
EP06116719 2006-07-06
EP06121258 2006-09-26
EP07103587 2007-03-06
PCT/EP2007/055535 WO2007141278A2 (en) 2006-06-06 2007-06-05 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Publications (2)

Publication Number Publication Date
EA200870594A1 true EA200870594A1 (ru) 2009-06-30
EA016717B1 EA016717B1 (ru) 2012-07-30

Family

ID=38686686

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870594A EA016717B1 (ru) 2006-06-06 2007-06-05 Моноклональное антитело человека, обладающее опсонизирующей фагоцитарной киллерной активностью в отношении enterococcus и staphylococcus aureus, и его применение

Country Status (13)

Country Link
US (4) US7960518B2 (ru)
EP (1) EP2024394B1 (ru)
JP (1) JP5586952B2 (ru)
KR (5) KR20200058579A (ru)
CN (1) CN101460518B (ru)
AU (1) AU2007255388B2 (ru)
CA (1) CA2654502C (ru)
EA (1) EA016717B1 (ru)
IL (2) IL195674A0 (ru)
MX (1) MX2008014978A (ru)
NO (1) NO20090063L (ru)
WO (1) WO2007141278A2 (ru)
ZA (1) ZA200809832B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2468021T3 (es) * 2004-05-27 2014-06-13 Crucell Holland B.V. Moléculas de unión que pueden neutralizar el virus de la rabia y usos de las mismas
AU2005293560B2 (en) * 2004-10-12 2011-10-06 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
JP5586952B2 (ja) 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
CN103351435B (zh) * 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
PL2059532T3 (pl) * 2006-09-07 2013-05-31 Crucell Holland Bv Ludzkie cząsteczki wiążące zdolne do neutralizowania wirusa grypy H5N1 i ich zastosowania
WO2009029132A2 (en) * 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
FI20085579A0 (fi) * 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
US8399624B1 (en) * 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
WO2012088247A2 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
EP3004161B1 (en) * 2013-05-31 2019-10-02 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
EP2889311B1 (en) 2013-12-30 2018-03-21 Albert-Ludwigs-Universität Freiburg Opsonic and protective monoclonal antibodies against gram-positive pathogens
AU2015206515B2 (en) 2014-01-15 2019-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cartilage targeting agents and their use
EP3415160B1 (en) 2014-03-04 2021-08-18 Klinikum der Universität München Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
EP3226911A1 (en) * 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
RS61781B1 (sr) 2014-12-05 2021-06-30 Memorial Sloan Kettering Cancer Center Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
EP4269594A3 (en) 2017-02-17 2023-12-20 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
EP3703688A2 (en) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
CN109406680A (zh) * 2018-12-19 2019-03-01 山东省食品药品检验研究院 超高效液相色谱-串联质谱法测定豆芽中10种喹诺酮类抗生素的方法
EP3899039A4 (en) * 2018-12-20 2022-09-14 The Johns Hopkins University TREATMENT OF TYPE 1 DIABETES AND OTHER AUTOIMMUNE DISEASES
WO2020206233A1 (en) * 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022011264A2 (en) * 2020-07-10 2022-01-13 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against rotavirus

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4901307A (en) 1986-10-17 1990-02-13 Qualcomm, Inc. Spread spectrum multiple access communication system using satellite or terrestrial repeaters
JPS6436463A (en) 1987-07-31 1989-02-07 Toshiba Corp Information processing system
US5103459B1 (en) 1990-06-25 1999-07-06 Qualcomm Inc System and method for generating signal waveforms in a cdma cellular telephone system
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH0918450A (ja) 1995-06-27 1997-01-17 Sony Corp 符号分割多重化送信装置
GB2310972B (en) 1996-03-07 2000-06-14 Motorola Ltd Communication system and operating method thereof
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
US5886988A (en) 1996-10-23 1999-03-23 Arraycomm, Inc. Channel assignment and call admission control for spatial division multiple access communication systems
US6335922B1 (en) 1997-02-11 2002-01-01 Qualcomm Incorporated Method and apparatus for forward link rate scheduling
US5914950A (en) 1997-04-08 1999-06-22 Qualcomm Incorporated Method and apparatus for reverse link rate scheduling
US6094428A (en) 1997-04-30 2000-07-25 Motorola, Inc. Method and apparatus for transmission and reception of a transmission rate in a CDMA communication system
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
FI110986B (fi) 1997-11-14 2003-04-30 Nokia Corp Menetelmä ja järjestelmä tiedonsiirtokapasiteetin optimaaliseksi hyödyntämiseksi solukkoradiojärjestelmässä
KR100279944B1 (ko) 1997-12-09 2001-02-01 윤종용 씨디엠에이셀룰러시스템에서의왈쉬코드그룹할당방법
US6700881B1 (en) 1998-03-02 2004-03-02 Samsung Electronics Co., Ltd. Rate control device and method for CDMA communication system
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2000078146A (ja) 1998-08-28 2000-03-14 Nippon Telegr & Teleph Corp <Ntt> Ａｂｒサービス用無線回線制御方法および該方法を用いた無線基地局と移動端末
US6421335B1 (en) 1998-10-26 2002-07-16 Nokia Telecommunications, Oy CDMA communication system and method using priority-based SIMA quality of service class
DE60043273D1 (de) 1999-04-15 2009-12-17 Crucell Holland Bv Verwendung von Rekombinanten Proteinen in Menschlichen Zellen
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
AU2001230424A1 (en) 2000-01-20 2001-07-31 Nortel Networks Limited Frame structure for variable rate wireless channels transmitting high speed data
EP1134994A1 (en) 2000-03-15 2001-09-19 Lucent Technologies Inc. Load balancing based on Walsh code usage
JP4694081B2 (ja) 2000-03-17 2011-06-01 クゥアルコム・インコーポレイテッド 無線通信システムにおける順方向リンクスケジューリング
AU2002345421B2 (en) 2001-06-15 2006-11-16 Crucell Holland B.V. Chimaeric phages
AU2002364740A1 (en) * 2001-12-21 2003-07-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20040052779A1 (en) 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2003219816A1 (en) * 2002-02-21 2003-09-09 Universita Degli Studi Di Pavia Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
CN100351260C (zh) 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
EP2439213B1 (en) 2004-04-21 2018-12-12 The Brigham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding antibodies and methods of use thereof
ES2468021T3 (es) 2004-05-27 2014-06-13 Crucell Holland B.V. Moléculas de unión que pueden neutralizar el virus de la rabia y usos de las mismas
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
JP5586952B2 (ja) 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用

Also Published As

Publication number Publication date
US20110268739A1 (en) 2011-11-03
US20120315278A1 (en) 2012-12-13
KR20200058579A (ko) 2020-05-27
JP2009542194A (ja) 2009-12-03
CA2654502A1 (en) 2007-12-13
US8241631B2 (en) 2012-08-14
KR20090024745A (ko) 2009-03-09
WO2007141278A3 (en) 2008-02-14
KR20220031126A (ko) 2022-03-11
AU2007255388A1 (en) 2007-12-13
EA016717B1 (ru) 2012-07-30
IL212592A0 (en) 2011-07-31
ZA200809832B (en) 2018-11-28
CN101460518B (zh) 2012-08-22
KR20210044318A (ko) 2021-04-22
JP5586952B2 (ja) 2014-09-10
EP2024394B1 (en) 2014-11-05
KR20190082996A (ko) 2019-07-10
AU2007255388B2 (en) 2013-07-04
CN101460518A (zh) 2009-06-17
MX2008014978A (es) 2008-12-09
IL212592A (en) 2015-04-30
US9428572B2 (en) 2016-08-30
CA2654502C (en) 2015-07-14
WO2007141278A2 (en) 2007-12-13
US8628776B2 (en) 2014-01-14
US20140099320A1 (en) 2014-04-10
NO20090063L (no) 2009-01-06
US7960518B2 (en) 2011-06-14
US20090169562A1 (en) 2009-07-02
EP2024394A2 (en) 2009-02-18
IL195674A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EA200602210A1 (ru) Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение
NO20091321L (no) Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001322A1 (ru) Вакцины против хламидиоза
ATE536376T1 (de) Humanes bindungsmolekül gegen cd1a
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
EA201190018A1 (ru) Миостатинсвязывающие белки
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MX2009005597A (es) Miembros de enlace para interleucina 6.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
CR20110470A (es) Proteínas de union a il-17
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM